SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Ginzler, E M
Right arrow Articles by Aranow, C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ginzler, E M
Right arrow Articles by Aranow, C
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Mycophenolate mofetil in lupus nephritis

E M Ginzler

Department of Medicine, SUNY-Downstate Medical Center, Brooklyn, NY, USA

C Aranow

Department of Medicine, Columbia Presbyterian Medical Centre, New York, NY, USA, ellen.ginzler{at}downstate.edu

There is an increasing body of literature suggesting the efficacy and tolerability of mycophenolate mofetil (MMF) for the treatment of lupus nephritis. The rationale for its use is based upon its successful profile as an immunosuppressive agent for prevention of allograft rejection, as well as studies in murine models of lupus which have reported improved renal function and animal survival compared to placebo. This report reviews the data regarding MMF therapy in murine lupus models, and describes the initial anecdotal experience with MMF in human lupus, especially in patients with glomerulonephritis who were unresponsive to corticosteroids and cyclophosphamide, or who had unacceptable toxicity on this standard of care regimen. The results of several nonblinded, controlled clinical trials are also described, in which MMF was compared to intravenous or oral cyclophosphamide in patients with lupus nephritis. MMF was found to be well tolerated, with most studies showing fewer infections than that associated with cyclophosphamide. Efficacy of MMF was at least equivalent to cyclophosphamide, and therefore appears to provide an alternative as a standard of care for induction and maintenance treatment of lupus nephritis.

Key Words: lupus nephritis • mycophenolate mofetil • SLE

Lupus, Vol. 14, No. 1, 59-64 (2005)
DOI: 10.1191/0961203305lu2061oa
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
G. R. Bihl, M. Petri, and D. M. Fine
Kidney biopsy in lupus nephritis: look before you leap
Nephrol. Dial. Transplant., July 1, 2006; 21(7): 1749 - 1752.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
F. Falcini, S. Trapani, L. Ricci, M. Resti, G. Simonini, and M. de Martino
Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment
Rheumatology, July 1, 2006; 45(7): 913 - 915.
[Full Text] [PDF]


Advertisement